AbbVie And FutureGen Biopharmaceutical Announce License Agreement To Develop FG-M701; Abbvie To Receive Exclusive Global License, FutureGen To Receive $150M Upfront Payment And Up To $1.56B In Milestones
AbbVie And FutureGen Biopharmaceutical Announce License Agreement To Develop FG-M701; Abbvie To Receive Exclusive Global License, FutureGen To Receive $150M Upfront Payment And Up To $1.56B In Milestones
艾伯維公司和未來根生物製藥宣佈許可協議，開發FG-M701；艾伯維公司將獲得獨家全球許可證，未來根將獲得1.5億美元的前期支付和高達15.6億美元的里程碑付款。
AbbVie And FutureGen Biopharmaceutical Announce License Agreement To Develop FG-M701; Abbvie To Receive Exclusive Global License, FutureGen To Receive $150M Upfront Payment And Up To $1.56B In Milestones
艾伯維公司和未來根生物製藥宣佈許可協議，開發FG-M701；艾伯維公司將獲得獨家全球許可證，未來根將獲得1.5億美元的前期支付和高達15.6億美元的里程碑付款。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。